← Back to Search

SGLT2 Inhibitor

Dapagliflozin for Alzheimer's Disease

Phase 1 & 2
Waitlist Available
Led By Jeffrey Burns, MD
Research Sponsored by Jeff Burns, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 weeks
Awards & highlights

Study Summary

This trial is testing whether the diabetes drug dapagliflozin can help treat Alzheimer's by measuring levels of a molecule called NAA. They will also explore whether dapagliflozin has any effect on metabolism, biomarkers, and cognition.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cerebral N Acetyl-Aspartate (NAA)
Other outcome measures
ADAS-Cog 14
Activated AKT levels
C-Reactive Protein (CRP)
+22 more

Side effects data

From 2018 Phase 4 trial • 30 Patients • NCT03006471
20%
Cervicovaginal infection
13%
Urinary tract infections
100%
80%
60%
40%
20%
0%
Study treatment Arm
Dapagliflozin
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: DapagliflozinExperimental Treatment1 Intervention
10 mg dapagliflozin oral tablet taken once daily for 12 weeks
Group II: Matching placeboPlacebo Group1 Intervention
Placebo oral tablet taken once daily for 12 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dapagliflozin
2014
Completed Phase 4
~64440

Find a Location

Who is running the clinical trial?

Jeff Burns, MDLead Sponsor
3 Previous Clinical Trials
208 Total Patients Enrolled
Jeffrey Burns, MDPrincipal InvestigatorUniversity of Kansas Medical Center
7 Previous Clinical Trials
1,231 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dapagliflozin In Alzheimer's Disease
Jeff Burns, MD 2019. "Dapagliflozin In Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03801642.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top